Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04447755 · OUTCOME

Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Smell Category

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) · Source last updated 2025-10-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Cycle 1 Day 1 (cycle = 28 days)

What was measured

A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the smell category is presented.

Analysis population: Per protocol, all participants who received suspension formulation were analyzed. Data were summarized in an overall safety analysis set irrespective of tumor type.

Groups in this outcome

All Tumor Types

Participants received lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Tumor Types10

Reported measurements

Super Bad
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types0Not reportedNot reportedNot reportedNot reported
Really Bad
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types0Not reportedNot reportedNot reportedNot reported
Bad
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types0Not reportedNot reportedNot reportedNot reported
Maybe Good or Maybe Bad
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types8Not reportedNot reportedNot reportedNot reported
Good
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types1Not reportedNot reportedNot reportedNot reported
Really Good
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types0Not reportedNot reportedNot reportedNot reported
Super Good
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Tumor Types1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Super Bad
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Really Bad
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Bad
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Maybe Good or Maybe Bad
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Good
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Really Good
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Super Good
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the smell category is presented.
groups
  1. description
    Participants received lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.
    id
    OG000
    title
    All Tumor Types
param Type
NUMBER
population Description
Per protocol, all participants who received suspension formulation were analyzed. Data were summarized in an overall safety analysis set irrespective of tumor type.
reporting Status
POSTED
time Frame
Cycle 1 Day 1 (cycle = 28 days)
title
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Smell Category
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice